Abstract
Objectives
To evaluate the blood levels, pharma-cokinetics and pharmacodynamic indices of pyrazinamide (PZA) in children suffering from tuberculosis, at doses administered under the weight band system of Revised National Tuberculosis Control Program of India (RNTCP) of India.
Design
Prospective, open-label, non-randomized single-dose study.
Setting
20 children in the age group 5–12 years attending outpatient tuberculosis clinic of a tertiary hospital.
Outcome Measures
Blood levels of pyrazinamide after single dose administration, as per the weight band system of RNTCP.
Results
Group I (n=7) included children who received pyrazinamide within the recommended 30–35 mg/kg dose (mean 31.9+0.8 mg/kg) and Group II (n=13) included those who received a dose lower than 30–35 mg/kg (mean 28.1±0.3 mg/kg). The Cmax (95% CI of difference 2.2, 13.2; P=0.008) and AUC (95% CI of difference 28.6, 208.1; P=0.01) were significantly lower in Group II. The duration of time for which the concentration was maintained above 25 μg ml−1 was 4–8 h in Group I and 3–5.5 h in Group II (95% CI of difference 0.1, 2.0; P=0.03). The half life, elimination rate constant, clearance and volume of distribution were comparable in the two groups. The ratios of Cmax and AUC to MIC (25 μg ml−1) in children were lower than that recommended for PZA in adults.
Conclusions
Lower blood concentrations are being attained in children receiving PZA doses under the existing weight band system of RNTCP of India. The weight bands may need to be revised and dose recommendations be based on pharmacokinetic and efficacy data in children.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
RNTCP Status Report. TB India 2007. Central TB Division, DGHS, MoHFW. New Delhi: Government of India; 2007.
Ramakrishnan CV, Janardhanam B, Krishnamurthy DV, Stott H, Subbammal S, Tripathy SP. Toxicity of pyrazinamide, administered once weekly in high dosage, in tuberculous patients. Bull World Health Organ. 1968;39:775–779.
Ellard GA. Absorption, metabolism and excretion of pyrazinamide in man. Tubercle. 1969;50:144–158.
Subbammal S, Krishnamurthy DV, Tripathy SP, Venkataraman P. Concentration of pyrazinamide attained in serum with different doses of the drug. Bull WHO. 1968;39:771–774.
Perlman DC, Segal Y, Rosenkranz S, Rainey PM, Peloquin CA, Remmel RP, et al. The clinical pharmacokinetics of pyrazinamide in HIV infected persons with tuberculosis. Clin Infect Dis. 2004;38:556–564.
Ormerod LP. Analysis of the frequency of drug reactions to antituberculosis drugs. Thorax. 1994; 49:433–434.
Singh J, Arora A, Garg PK, Thakur VS, Pande JN, Tandon RK. Antituberculosis treatment induced hepatotoxicity: role of predictive factors. Post Grad Med J. 1995;71:359–362.
Roy V, Tekur U, Chopra K. Pharmacokinetics of pyrazinamide in children suffering from pulmonary tuberculosis. Int J Tuberc Lung Dis. 1999;3:133–137.
McIlleron H, Willemse M, Schaaf HS, Smith PJ, Donald PR. Pyrazinamide plasma concentrations in young children with tuberculosis. Pediatr Infect Dis J. 2011;30:262–265.
Mitchison DA. Basic mechanisms of chemotherapy. Chest. 1979; 76(suppl):771–781.
Zhu M, Burman WJ, Steiner P, Stambaugh JJ, Ashkin D, Bulpitt AE, et al. Population pharmacokinetic modeling of pyrazinamide in children and adults with tuberculosis. Pharmacotherapy. 2002;22:686–695.
Nueremberger E, Grosset J. Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections. Eur J Microbiol Infect Dis. 2004;23:243–255.
Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs. 2002;62:2169–2183.
Gumbo T. New susceptibility breakpoints for first antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic and population pharmacokinetic variability. Antimicrob Agents Chemother. 2010;54:1484–1491.
Gupta P, Roy V, Sethi GR, Mishra TK. Pyrazinamide blood concentrations in children suffering from tuberculosis: a comparative study at two doses. Br J Clin Pharmacol. 2008;65:423–427.
Lacroix C, Hoang TP, Nouveau J, Guyonnaud C, Laine G, Duwoos H, Lafont O. Pharmacokinetics of pyrazinamide and its metabolites in healthy subjects. Eur J Clin Pharmacol. 1989;36:395–400.
Kearns GL, Reed MD. Clinical pharmacokinetics in infants and children: A reappraisal. Clin Pharmacokinet. 1989; 17(suppl): 29–67.
Te Water Naude JM, Donald PR, Hussey GD, Kibel MA, Louw A, Perkins DR, et al. Twice weekly vs. daily chemotherapy for childhood tuberculosis. Pediatr Infect Dis J. 2000;19:405–410.
Rapid advice: treatment of tuberculosis in children. WHO 2010. WHO/HTM/TB/2010.13. Available from:http://whqlibdoc.who.int/publications/2010/9789241500449_eng.pdf. Accessed on april 16, 2011.
CDC. Recommendations and Report. Treatment of Tuberculosis. American Thoracic Society, CDC and Infectious Disease Society of America. MMWR Morb Mortal Wkly Rep. 2003;52:1–77.
Ormerod LP, Citron KM, Darbyshire JH, Smith ML. Chemotherapy and management of tuberculosis in the United Kingdom: Recommendations of the Joint Tuberculosis Committee of the British Thoracic Society. Thorax. 1990;45:403–408.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Roy, V., Sahni, P., Gupta, P. et al. Blood levels of pyrazinamide in children at doses administered under the revised national tuberculosis control program. Indian Pediatr 49, 721–725 (2012). https://doi.org/10.1007/s13312-012-0164-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13312-012-0164-8